Malta officially legalised medicinal cannabis in April 2018, with the adoption of the Production of Cannabis for Medicinal and Research Purposes Act.
Keen to be a central enabler of Europe’s medical cannabis sector, Malta is leveraging its renowned pharmaceutical regulatory framework to position itself as a strategic hub for the global cannabis market.
A handful of leading cannabis companies have chosen to set up facilities in Malta, taking advantage of the country’s expertise in pharmaceutical manufacturing and business-friendly operating environment.
Materia operates a state-of-the-art medical cannabis production facility nestled in the heart of Malta’s Ħal Far industrial zone.
This site is our manufacturing hub, where we process cannabis raw material into EU GMP quality flower to be distributed throughout Europe and the world.
Products made here are helping patients improve their quality of life in Germany, Malta and soon the UK.
Amidst the dozens of companies who received government approval to build cannabis facilities in Malta, Materia was the third to achieve its full licence, the second to begin sales from its site and the first to export cannabis medicine from Malta for sale in other countries.
We believe Malta will play an important role in the global cannabis supply chain, as it has done within the broader pharmaceuticals sector for decades.
We are proud to represent this new pillar in Malta’s historied medicines manufacturing industry.